https://www.selleckchem.com/pr....oducts/LY2228820.htm
As a pooled donor blood product, cryoprecipitate (cryo) carries risks of pathogen transmission. Pathogen inactivation (PI) improves the safety of cryoprecipitate, but its effects on haemostatic properties remain unclear. This study investigated protein expression in samples of pathogen inactivated cryoprecipitate (PI-cryo) using non-targeted quantitative proteomics and in vitro haemostatic capacity of PI-cryo. Whole blood (W- and apheresis (APH)-derived plasma was subject to PI with INTERCEPT Blood System (Cerus Corporation, Concord
Like
Comment
Share
